Until there are more validated biomarkers to direct treatment decisions, many physicians use patient age to decide what therapy to give their patients. Literature data report that older patients often go undertreated because ...
Oct 15, 2012
0
0
(HealthDay)—Abraxane (paclitaxel protein-bound) has been approved by the U.S. Food and Drug Administration—in combination with the drug carboplatin—to treat advanced or spreading non-small cell lung cancer among people ...
Oct 14, 2012
0
0
Treatment with the drug sorafenib as a third or fourth line therapy does not result in improved overall survival among patients with advanced non-small cell lung cancer (NSCLC), according to findings released at the ESMO ...
Sep 29, 2012
0
0
Researchers at Kansas State University have developed a simple blood test that can accurately detect the beginning stages of cancer.
Sep 26, 2012
0
0
German pharmaceuticals maker Merck KGaA said Tuesday it is withdrawing its application for its drug Erbitux to be used to treat patients with lung cancer.
Sep 18, 2012
0
0
Lung cancer patients with a history of smoking have 10 times more genetic mutations in their tumors than those with the disease who have never smoked, according to a new study from Washington University School of Medicine ...
Sep 13, 2012
0
0
Lung cancer is a leading cause of death worldwide and is associated with very low survival rates. Two new genome-sequencing studies have uncovered novel genes involved in the deadly disease, as well as striking differences ...
Sep 13, 2012
0
0
Crizotinib is effective in shrinking tumors in patients with anaplastic lymphoma receptor tyrosine kinase (ALK) positive non-small cell lung cancer, a cancer commonly found in people who never smoked, and should be the standard ...
Sep 6, 2012
0
0
A study of survival data for Stage III, non-small cell lung cancer (NSCLC) patients at the University of Maryland's Greenebaum Cancer Center in Baltimore indicates that marital status and race can significantly impact patient ...
Sep 6, 2012
0
0
Treatment with pemetrexed, carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab (Pem+Cb+B) is no better than standard therapy with paclitaxel, carboplatin and bevacizumab followed by bevacizumab ...
Sep 6, 2012
0
0
